2 unknown, 1 completed. 1 Not applicable, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 1 | Completed 1 |
| Phase 2 | 1 | Unknown 1 |
| Phase 3 | 1 | Unknown 1 |
Follow Bioxytran Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| To Evaluate the Safety, Efficacy,and Pharmacokinetics of Orally Administered Prolectin-M Prolectin-M - COVID-19, SARS CoV 2 Infection | Phase 2 | Unknown | Bioxytran Inc. | 40 | 2023-09-01 | 2023-09-28 |
| PROlectin M, a Nucleocapsid TErminal GaleCTin Antagonist for COVID-19 Galactomannan, PLACEBO - COVID-19, COVID-19 Pandemic | Phase 3 | Unknown | Bioxytran Inc. | 408 | 2022-04-01 | 2022-03-09 |
| Prolectin-M in COVID-19 Patients Having Mild to Moderate Symptoms Not Requiring Oxygen Support. Prolectin-M; a (1-6)-alpha-D-Mannopyranose class, Standard of Care - COVID-19 | Not applicable | Completed | Composite Interceptive Med Science | 10 | 2020-09-15 | 2020-10-19 |
COVID-19 (3) · Cytokine Release Syndrome (1)
galactomannan (2) · Standard of Care (1)
India (1)
Sunitha Mali (1)